News
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...
Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results